- About Us
Enteris BioPharma is a privately held, biotechnology company offering innovative formulation solutions built around its proprietary drug delivery technologies.
Since its founding in 2013, Enteris has advanced multiple internal and external programs leveraging its Peptelligence™ platform. The technology has been developed and proven effective over the last decade to enable the safe delivery of peptide-based therapeutics and other molecules with low oral bioavailability.
Currently, Enteris BioPharma’s internal product pipeline consists of Ovarest™ (oral leuprolide tablet), currently being evaluated in a Phase 2a study for endometriosis, and Tobrate™ (oral tobramycin tablet) for the treatment of uncomplicated urinary tract infection (uUTI). External market analyses demonstrate projected annual U.S. revenue potential for these two products in excess of $1 billion in aggregate.
Additionally, Enteris BioPharma’s oral peptide delivery technology is the subject of several active external development programs, the most advanced of which include Tarsa Therapeutics’ TBRIA, an oral calcitonin for patients with postmenopausal osteoporosis, and an oral formulation of Cara Therapeutics’ CR845, a potent peripheral kappa opioid receptor agonist who recently announced top-line results from its Phase 2b clinical trial in chronic pain patients with osteoarthritis of the hip or knee.